• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cardinal Health announces approved science-based climate targets; expands focus across the supply chain

    3/15/24 8:00:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email

    DUBLIN, Ohio, March 15, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions reduction targets. Targets are considered science-based if they align with what the latest climate science says is necessary to limit global warming to 1.5°C above pre-industrial levels.

    Cardinal Health Logo (PRNewsfoto/Cardinal Health)

    "We are committed to reducing our impact on the environment and contributing to a more sustainable world," said Megan Maltenfort, Cardinal Health's VP of Environmental, Social and Governance (ESG). "We value our work with SBTi and will continue taking proactive steps to address climate change and to reduce the environmental impact of our products and processes."

    With the SBTi approval, Cardinal Health commits to the following science-based targets:

    • reduce absolute Scope 1 and 2 GHG emissions 50% by fiscal 2030 from a fiscal 2019 base year.* 
    • 75% of its suppliers by spend, covering purchased goods and services and upstream transportation and distribution, will have science-based targets by fiscal 2028.

    These approved targets represent an expansion of the company's current goal of reducing Scope 1 and 2 GHG emissions, announced in September 2021; the inclusion of Scope 3 emissions from our supply chain has made the goal more ambitious.

    "As we work to achieve our targets, we will collaborate with partners along our supply chain to collectively address the impacts of climate change," Maltenfort said.

    By the end of fiscal 2023, Cardinal Health had reduced its Scope 1 and 2 emissions by 13% from a fiscal 2019 base year. In addition, the company continues to invest in energy efficiency opportunities in its distribution and manufacturing sites and is looking to expand its use of renewable energy across the enterprise. Cardinal Health reports on progress toward its climate goals in its annual Environmental, Social and Governance (ESG) Report.

    The Science Based Targets initiative (SBTi) is a global body enabling businesses to set ambitious emissions reductions targets in line with the latest climate science. It is a collaboration between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF) and one of the We Mean Business Coalition commitments. 

    *The target boundary includes land-related emissions and removals from bioenergy feedstocks.

    About Cardinal Health

    Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business, operations in more than 30 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.

    Contacts:

    Media:  Erich Timmerman, [email protected] and 614.757.8231       

    Investors: Matt Sims, [email protected] and 614.553.3661

    Cautions concerning forward-looking statements

    This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various metrics, accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include the risk that we may fail to achieve our emissions targets or could be unsuccessful at reducing the emissions in our supply chain and the risk that our attempts to reduce emissions may have unintended consequences or could negatively impact our business performance. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This news release reflects management's views as of March 15, 2024. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this news release can or will be achieved or completed.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cardinal-health-announces-approved-science-based-climate-targets-expands-focus-across-the-supply-chain-302089740.html

    SOURCE Cardinal Health

    Get the next $CAH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAH

    DatePrice TargetRatingAnalyst
    1/9/2026Neutral → Buy
    Citigroup
    12/9/2025$243.00Overweight
    Barclays
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $CAH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardinal Health report highlights cost savings and provider confidence in biosimilars

    New analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology leading in adoption and accessibility gains.DUBLIN, Ohio, Feb. 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today released its 2026 Biosimilars Report: Driving access and patient outcomes in physician practices, which highlights the substantial savings biosimilars have delivered to the U.S. healthcare system and the strong confidence providers have in these treatments. "Since 2015, biosimilars have generated more than $56 billion i

    2/24/26 7:00:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on April 15, 2026 to shareholders of record at the close of business on April 1, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

    2/12/26 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 19% to $65.6 billionGAAP1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35Cardinal Health completes annual baseline share repurchase of $750 millionCardinal Health reaches targeted leverage range3DUBLIN, Ohio, Feb. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of fiscal year 2025. Second quarter GAAP operating earnings increased 29%

    2/5/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    SEC Filings

    View All

    Cardinal Health Inc. filed SEC Form 8-K: Leadership Update

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    3/5/26 7:07:59 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by Cardinal Health Inc.

    10-Q - CARDINAL HEALTH INC (0000721371) (Filer)

    2/5/26 8:47:09 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    2/5/26 6:47:19 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cardinal Health upgraded by Citigroup

    Citigroup upgraded Cardinal Health from Neutral to Buy

    1/9/26 8:24:26 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Barclays initiated coverage on Cardinal Health with a new price target

    Barclays initiated coverage of Cardinal Health with a rating of Overweight and set a new price target of $243.00

    12/9/25 8:43:24 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

    6/3/25 7:24:57 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Chief Information Officer Greene Michelle D. sold $627,387 worth of shares (2,746 units at $228.47), decreasing direct ownership by 18% to 12,230 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    3/3/26 4:11:18 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Chief Financial Officer Alt Aaron E covered exercise/tax liability with 1,914 shares and sold $524,964 worth of shares (2,328 units at $225.50), decreasing direct ownership by 14% to 26,408 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    2/18/26 4:25:35 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Director Hall Patricia Hemingway sold $918,880 worth of shares (4,000 units at $229.72), decreasing direct ownership by 12% to 28,264 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    2/10/26 4:13:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/13/24 5:01:02 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    1/30/24 1:39:03 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/14/23 12:37:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Financials

    Live finance-specific insights

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on April 15, 2026 to shareholders of record at the close of business on April 1, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

    2/12/26 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 19% to $65.6 billionGAAP1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35Cardinal Health completes annual baseline share repurchase of $750 millionCardinal Health reaches targeted leverage range3DUBLIN, Ohio, Feb. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of fiscal year 2025. Second quarter GAAP operating earnings increased 29%

    2/5/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Nov. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of

    11/4/25 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Carlisle Companies Announces Leadership Appointments

    Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

    5/16/25 4:05:00 PM ET
    $CAH
    $CSL
    $SUM
    Other Pharmaceuticals
    Health Care
    Specialty Chemicals
    Industrials

    Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    3/10/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care